AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19018865 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance with thalidomide after ASCT
Number of subjects: 0
Study 19018865 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of an alkylating drug with a novel agent
Number of subjects: 0
Study 19018865 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids plus bortezomib, thalidomide or lenalidomide
Number of subjects: 0
Study 17243997 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD + NBM + GTR (test)
Number of subjects: 19
Study 17243997 — intervention group
Group type: COMPARATOR
Intervention: OFD alone (control)
Number of subjects: 19
Study 15747820 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual appliances (Group LI)
Number of subjects: 60
Study 15747820 — intervention group
Group type: COMPARATOR
Intervention: Labial appliances (Group LA)
Number of subjects: 60
Study 15747820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 12215058 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 12
Study 12215058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and sertraline
Number of subjects: 12
Study 12215058 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine and citalopram
Number of subjects: 12
Study 12215058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 12
Study 12215058 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 12
Study 12215058 — intervention group
Group type: COMPARATOR
Intervention: Serotonergic antidepressants
Number of subjects: 12
Study 9626835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 255
Study 8087361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 27
Study 8087361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2811958 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled coffee (4 to 6 cups a day)
Number of subjects: 107
Study 2811958 — intervention group
Group type: COMPARATOR
Intervention: Filtered coffee (4 to 6 cups a day)
Number of subjects: 107
Study 2811958 — intervention group
Group type: COMPARATOR
Intervention: No coffee
Number of subjects: 107
Study 2811958 — intervention group
Group type: COMPARATOR
Intervention: Filtered coffee
Number of subjects: 107
Study 30939272 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication Skills Intensive training
Number of subjects: 65
Study 28109543 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (1.5 mg or 3 mg) with reduced cyclosporine
Number of subjects: 95
Study 28109543 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate sodium and standard exposure cyclosporine
Number of subjects: 95
Study 25464424 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (12 week standardized aerobic dynamic exercise training program)
Number of subjects: 93
Study 25464424 — intervention group
Group type: COMPARATOR
Intervention: Control (continued lifestyle and received care as usual)
Number of subjects: 93
Study 25798518 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality foster care with specialized training and support
Number of subjects: 2
Study 25798518 — intervention group
Group type: COMPARATOR
Intervention: Government-sponsored foster care
Number of subjects: 2
Study 22795453 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release mixed amphetamine salts (MAS-ER) and topiramate
Number of subjects: 81
Study 22795453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 20689928 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients confident in extubation success (confidents; n = 115)
Number of subjects: 211
Study 20689928 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not confident in extubation success (non-confidents; n = 38)
Number of subjects: 211
Study 20689928 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients not subjected to interview; n = 58)
Number of subjects: 211
Study 17279307 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐mm LigaSure
Number of subjects: 30
Study 17279307 — intervention group
Group type: COMPARATOR
Intervention: 10‐mm LigaSure
Number of subjects: 30
Study 16218799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg
Number of subjects: 174
Study 16218799 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 174
Study 16218799 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Fenofibrate + Pravastatin)
Number of subjects: 174
Study 12359197 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily aspiration of seroma
Number of subjects: 36
Study 12359197 — intervention group
Group type: COMPARATOR
Intervention: Aspiration as required by patient symptoms
Number of subjects: 36
Study 10416042 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 100 mg twice daily
Number of subjects: 22
Study 10416042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7559695 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (administered at 12 hours preoperatively and 12 and 36 hours postoperatively)
Number of subjects: 156
Study 7559695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enoxaparin)
Number of subjects: 156
Study 7559695 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 156
Study 7559695 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study 2288819 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG)
Number of subjects: 40
Study 2288819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometric exercise (BEE)
Number of subjects: 40
Study 2288819 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine infusion (TI)
Number of subjects: 40
Study 7234190 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 0
Study 7234190 — intervention group
Group type: COMPARATOR
Intervention: No Calcitonin (Control)
Number of subjects: 0
Study 31487365 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based (CB) intervention
Number of subjects: 0
Study 31487365 — intervention group
Group type: COMPARATOR
Intervention: Home-based (HB) intervention
Number of subjects: 0
Study 28085904 — intervention group
Group type: EXPERIMENTAL
Intervention: Toy with smaller-sized meal bundle (420 calories)
Number of subjects: 109
Study 28085904 — intervention group
Group type: COMPARATOR
Intervention: Regular-sized meal bundle (580 calories)
Number of subjects: 109
Study 25845222 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of kakkonein (2 mL) into bilateral Fengchi (GB 20), once every other day for 8 weeks
Number of subjects: 135
Study 25845222 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (bilateral GB 20 acupoints punctured with filiform needles), once every other day for 8 weeks
Number of subjects: 135
Study 25845222 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of compound levodopa (125 mg, twice a day) for 8 weeks
Number of subjects: 135
Study 23975654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine co-administered with bupropion
Number of subjects: 0
Study 23975654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine co-administered with fluconazole
Number of subjects: 0
Study 23975654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine co-administered with ketoconazole
Number of subjects: 0
Study 23975654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine co-administered with rifampicin
Number of subjects: 0
Study 23975654 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine co-administered with ethinyl estradiol/levonorgestrel
Number of subjects: 0
Study 23975654 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine co-administered with 5'-hydroxyomeprazole
Number of subjects: 0
Study 20869142 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating-bearing
Number of subjects: 0
Study 20869142 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing arthroplasty
Number of subjects: 0
Study 19215678 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil (SBO)
Number of subjects: 16
Study 19215678 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran oil (RBO)
Number of subjects: 16
Study 19215678 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil (PO)
Number of subjects: 16
Study 19215678 — intervention group
Group type: EXPERIMENTAL
Intervention: RBO/PO mixture (3:1)
Number of subjects: 16
Study 19215678 — intervention group
Group type: COMPARATOR
Intervention: Control diet (8-week period)
Number of subjects: 16
Study 17918294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 20 mg/m(2), days 1‐5, every 21 days (arm A, n=171)
Number of subjects: 335
Study 17918294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m(2)/weekly (arm B, n=164)
Number of subjects: 335
Study 17918294 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 335
Study 15503750 — intervention group
Group type: EXPERIMENTAL
Intervention: PRRR training (five 8-hour training modules)
Number of subjects: 232
Study 15503750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 232
Study 11522955 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with parietal lobe pathology
Number of subjects: 0
Study 11522955 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 9294777 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of bovine TSH, 10 units daily for 3 days
Number of subjects: 17
Study 9294777 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral administration of L‐triiodothyronine 75 micrograms for 7 days
Number of subjects: 17
Study 9294777 — intervention group
Group type: COMPARATOR
Intervention: Normal responses (> 50%) in nine subjects
Number of subjects: 17
Study 7870742 — intervention group
Group type: EXPERIMENTAL
Intervention: New generation antidepressants (maprotiline, mianserin, viloxazine, trazodone, nomifensine, fluvoxamine, fluoxetine)
Number of subjects: 0
Study 7870742 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 7870742 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 3346364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (100 mg, three times daily for 4 days, then 50 mg, three times daily for 90 days)
Number of subjects: 66
Study 3346364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 3346364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 66
Study 29724350 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 610
Study 29724350 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stents
Number of subjects: 610
Study 27073063 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging-guided focused ultrasound surgery
Number of subjects: 49
Study 27073063 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 49
Study 27073063 — intervention group
Group type: COMPARATOR
Intervention: Randomized participants
Number of subjects: 49
Study 27073063 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized participants
Number of subjects: 49
Study 25023791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial bone marrow cell (BMC) injection (97 ± 13 × 10(6) BMCs)
Number of subjects: 120
Study 22680341 — intervention group
Group type: EXPERIMENTAL
Intervention: Namisol® (5 mg THC) - Sublingual administration
Number of subjects: 12
Study 22680341 — intervention group
Group type: EXPERIMENTAL
Intervention: Namisol® (6.5 mg and 8.0 mg THC) - Oral administration
Number of subjects: 12
Study 22680341 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 12
Study 19763743 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DPO) targeting hemoglobin (Hb) of 12-13 g/dl
Number of subjects: 0
Study 19763743 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa (EPO) targeting conventional Hb
Number of subjects: 0
Study 19763743 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of anemia to 11 g/dl or more
Number of subjects: 0
Study 18417519 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical nerve stimulation)
Number of subjects: 45
Study 18417519 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 45
Study 15885612 — intervention group
Group type: EXPERIMENTAL
Intervention: Engineering schemes incorporating vertical deflections (speed humps or cushions)
Number of subjects: 0
Study 15885612 — intervention group
Group type: COMPARATOR
Intervention: Safety cameras
Number of subjects: 0
Study 15885612 — intervention group
Group type: EXPERIMENTAL
Intervention: Other types of engineering schemes
Number of subjects: 0
Study 11952885 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (S) 40 mg for 6 weeks, S 80 mg for 6 weeks, S 80 mg for 24 weeks
Number of subjects: 47
Study 11952885 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (A) 20 mg for 6 weeks, A 40 mg for 6 weeks, A 80 mg for 24 weeks
Number of subjects: 47
Study 11952885 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (A) 80 mg
Number of subjects: 47
Study 11952885 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (S) 80 mg
Number of subjects: 47
Study 9606771 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-TENS (1.7 Hz) for 60 min, five days a week for three months
Number of subjects: 44
Study 9606771 — intervention group
Group type: COMPARATOR
Intervention: Control group (physiotherapy only)
Number of subjects: 44
Study 7617812 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium-TCA treatment
Number of subjects: 20
Study 7617812 — intervention group
Group type: COMPARATOR
Intervention: TCA-placebo treatment
Number of subjects: 20
Study 2095133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen sugar-coated tablets (Dolo-Dolgit) 600 mg
Number of subjects: 16
Study 2095133 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen film-coated tablets 600 mg (reference preparation)
Number of subjects: 16
Study 453256 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-gentamicin
Number of subjects: 200
Study 453256 — intervention group
Group type: COMPARATOR
Intervention: Penicillin-gentamicin
Number of subjects: 200
Study 31697573 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (0.425 g, 14% of ADI)
Number of subjects: 17
Study 31697573 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (0.136 g, 20% of ADI)
Number of subjects: 17
Study 31697573 — intervention group
Group type: EXPERIMENTAL
Intervention: NNS treatment (aspartame and sucralose)
Number of subjects: 17
Study 31029381 — intervention group
Group type: EXPERIMENTAL
Intervention: 100–300 μm microspheres
Number of subjects: 138
Study 31029381 — intervention group
Group type: EXPERIMENTAL
Intervention: 300–500 μm microspheres
Number of subjects: 138
Study 31029381 — intervention group
Group type: EXPERIMENTAL
Intervention: 100–300 μm followed by 300–500 μm microspheres
Number of subjects: 138
Study 31029381 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 138
Study 28157599 — intervention group
Group type: EXPERIMENTAL
Intervention: One Session Treatment for specific phobias
Number of subjects: 251
Study 25155700 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about voluntary medical male circumcision (VMMC) and HIV risk
Number of subjects: 1335
Study 24517053 — intervention group
Group type: EXPERIMENTAL
Intervention: Huzhang Tongfeng Granule + Jinhuang Ointment (acute phase); Yinlian Tongfeng Granule (remission phase)
Number of subjects: 90
Study 24517053 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac Sodium Sustained Release Capsule + Jinhuang Ointment (acute phase); Benzbromarone (remission phase)
Number of subjects: 90
Study 24517053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 21768630 — intervention group
Group type: COMPARATOR
Intervention: TKR without synovectomy
Number of subjects: 67
Study 21768630 — intervention group
Group type: EXPERIMENTAL
Intervention: TKR with synovectomy
Number of subjects: 67
Study 19505198 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem tartrate extended-release taken in combination with escitalopram
Number of subjects: 379
Study 19505198 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with escitalopram
Number of subjects: 379
Study 16918596 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hyaluronic acid (HA) 0.2%
Number of subjects: 120
Study 16918596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 14728633 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training of knee extensors and flexors three times a week for 12 weeks
Number of subjects: 21
Study 14728633 — intervention group
Group type: COMPARATOR
Intervention: Social activities supervised by an occupation therapist
Number of subjects: 21
Study 14728633 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 21
Study 11523256 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Misgav Ladach technique
Number of subjects: 172
Study 11523256 — intervention group
Group type: COMPARATOR
Intervention: Misgav Ladach technique
Number of subjects: 172
Study 11523256 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel technique
Number of subjects: 172
Study 9760805 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 34
Study 9760805 — intervention group
Group type: EXPERIMENTAL
Intervention: CYFRA 21.1
Number of subjects: 34
Study 9760805 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 34
Study 9760805 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF and CYFRA 21.1
Number of subjects: 34
Study 7836524 — intervention group
Group type: EXPERIMENTAL
Intervention: 62.5 microM ascorbate in HTF medium
Number of subjects: 83
Study 7836524 — intervention group
Group type: EXPERIMENTAL
Intervention: 62.5 microM ascorbate in Ham's F‐10 medium
Number of subjects: 83
Study 7836524 — intervention group
Group type: COMPARATOR
Intervention: Control group (absence of ascorbate) in HTF medium
Number of subjects: 83
Study 7836524 — intervention group
Group type: COMPARATOR
Intervention: Control group (absence of ascorbate) in Ham's F‐10 medium
Number of subjects: 83
Study 3296734 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (2 mg/kg/dose)
Number of subjects: 29
Study 3296734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (2 mg/kg/dose)
Number of subjects: 29
Study 3296734 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine (10 mg/dose)
Number of subjects: 29
Study 3296734 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (oral and intravenous)
Number of subjects: 29
Study 3296734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral and intravenous metoclopramide
Number of subjects: 29
Study 28947382 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy-led exercise program for 12 weeks
Number of subjects: 43
Study 27935580 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance treatment
Number of subjects: 2732
Study 27935580 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance treatment in patients aged >74 years
Number of subjects: 2732
Study 27935580 — intervention group
Group type: COMPARATOR
Intervention: Observation only patients
Number of subjects: 2732
Study 27935580 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2732
Study 24726095 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 155
Study 24726095 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg twice daily
Number of subjects: 155
Study 24726095 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily plus tenofovir and lamivudine
Number of subjects: 155
Study 23188890 — intervention group
Group type: EXPERIMENTAL
Intervention: Scratch card technology for random allocation concealment
Number of subjects: 0
Study 23188890 — intervention group
Group type: COMPARATOR
Intervention: Sequentially numbered, opaque, sealed envelopes (SNOSE) system
Number of subjects: 0
Study 21559998 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement prior to scheduled surgery (group 1)
Number of subjects: 28
Study 21559998 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative colonic lavage (IOCL) (group 2)
Number of subjects: 28
Study 21559998 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement (group 1)
Number of subjects: 28
Study 21559998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 18807201 — intervention group
Group type: COMPARATOR
Intervention: Medium income
Number of subjects: 188
Study 18807201 — intervention group
Group type: COMPARATOR
Intervention: High income
Number of subjects: 188
Study 18807201 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking adjustment
Number of subjects: 188
Study 18807201 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression adjustment
Number of subjects: 188
Study 18807201 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger symptoms adjustment
Number of subjects: 188
Study 16557039 — intervention group
Group type: EXPERIMENTAL
Intervention: CD only
Number of subjects: 0
Study 16557039 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD only
Number of subjects: 0
Study 16557039 — intervention group
Group type: EXPERIMENTAL
Intervention: CD plus BPD
Number of subjects: 0
Study 16557039 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 12690366 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation test (PAT) responders (esotropia <= 8 PD at distance and near with four-dot fusion at near)
Number of subjects: 65
Study 12690366 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders (exotropia at distance or lack of four-dot fusion at near)
Number of subjects: 65
Study 12690366 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders whose angles built with prism
Number of subjects: 65
Study 12690366 — intervention group
Group type: COMPARATOR
Intervention: Patients with esotropia <= 8 PD at near with prisms preoperatively
Number of subjects: 65